Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Andrographolide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Mar 2018 New trial record